Passage Bio, Inc. (PASG) Prices 12M Share IPO at $18/Sh

Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options, today announced the pricing of its initial public offering of 12,000,000 shares of common stock at a public offering price of $18.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Passage Bio, are expected to be $216.0 million. All of the shares are being offered by Passage Bio. The offering is expected to close on March 3, 2020, subject to customary closing conditions. In addition, Passage Bio has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

The shares are expected to begin trading on the Nasdaq Global Select Market on February 28, 2020 under the ticker symbol “PASG.”

J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Chardan is acting as lead manager for the offering.

You May Also Be Interested In

• SK hynix files for Nasdaq IPO under ticker symbol SKHY
• Castle Biosciences CFO Frank Stokes named Houston Business Journal honoree
• Absci prices $100M stock offering with Eli Lilly among investors